biosimilar trastuzumab: a cost effective alternative for breast cancer treatment
Published 7 years ago • 493 plays • Length 1:05Download video MP4
Download video MP3
Similar videos
-
0:32
the potential of biosimilars in cancer treatment
-
1:26
biosimilars: the future of treating breast cancer
-
1:54
biosimilars are alternatives for original antibodies
-
0:54
biosimilars: a promising new therapeutic option in cancer treatment
-
3:14
abp 980, a trastuzumab biosimilar in combination with pertuzumab
-
2:33
positive results for trastuzumab biosimilar ct-p6 in her2 early breast cancer
-
12:12
breast cancer treatment - trastuzumab biosimilars
-
1:47
the use of trastuzumab and biosimilars in the treatment of breast cancer
-
1:47
results of a phase iii trial on ct-p6, a trastuzumab biosimilar candidate, in early breast cancer
-
1:29
tuxedo-1: trastuzumab deruxtecan for the treatment of her2-positive breast cancer brain metastases
-
2:15
treatment strategies for her2 metastatic breast cancer
-
3:38
biosimilar trastuzumab
-
2:43
lilac: comparing cardiac safety of abp 980 with trastuzumab
-
2:39
the role of biomarkers in guiding treatment for early-stage breast cancer
-
4:29
pertuzumab, trastuzumab and cyclophosphamide in older patients with her2 breast cancer
-
4:16
adjuvant treatment for stage i her2 breast cancer
-
2:40
biosimilars: a new approach to cancer treatment in brazil
-
2:06
mylan biosimilar as good as herceptin in advanced breast cancer
-
2:00
tulip: trastuzumab duocarmazine improved pfs in pre-treated her2 breast cancer